---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-052420"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:12:31.920434+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics presents SEQUOIA-HCM baseline data: 282 patients enrolled, results due by end 2023

## Summary
- SEQUOIA-HCM enrolled 282 patients with symptomatic obstructive HCM; one third from US, half from Europe/Israel, remainder from China.
- Mean age 59.1 years, 40.4% female, 78.7% white; baseline NYHA class II 75.9%, III 23.8%, IV 0.4%.
- Background therapy: beta-blockers 61%, calcium channel blockers 26.6%, disopyramide 12.8%.
- Key blinded baseline data include LVEF, LVOT gradients, and NT-proBNP; top-line results still expected by end of 2023.

## SEC filing metadata
- accession: 0000950170-23-052420
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/0000950170-23-052420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/cytk-20231006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-052420
- JSON: https://secwatch.observer/filing/0000950170-23-052420.json
- Plain text: https://secwatch.observer/filing/0000950170-23-052420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.